




Virus

Retroviridae

ssRNA+



Opportunistic Mycoses

Name

Opportunistic Mycoses –

Fungal infections that occur **primarily in immunocompromised individuals** (e.g., HIV, transplant patients, chemotherapy, diabetes).

Morphology

- Caused by **yeasts or molds**
- Most are **monomorphic**, not dimorphic
- Appear as **hyphae, pseudohyphae, or yeast cells** depending on species

Habitat & Reservoir

- Ubiquitous in **environment** (soil, air, decaying matter) or part of **normal flora** (e.g., *Candida*)
- Inhalation, catheter contamination, gut translocation, or direct inoculation**

Pathogenic Form

- No environmental-to-yeast switch like dimorphic fungi
- Pathogenic form = **same as colonizing or environmental form**

Infective Agents


- Candida* spp.** – *Candida albicans*, etc.
- Aspergillus* spp.** – *Aspergillus fumigatus*
- Cryptococcus neoformans***
- Mucor*, *Rhizopus* (*Zygomycetes*/Mucormycosis)**
- Fusarium*, *Penicillium marneffei* (Talaromyces) in endemic areas**
- Pneumocystis jirovecii***

Virulence Factors

- Biofilm formation (*Candida*)
- Angioinvasion (*Aspergillus*, *Mucor*)
- Capsule (*Cryptococcus*)
- Resistance to oxidative burst
- Thermotolerance and enzyme production



Oral candidiasis (thrush)



Candida albicans




Cryptosporidium parvum



Aspergillus species

Clinical Manifestations

- Candida*:** oral thrush, esophagitis, vaginitis, bloodstream infections (candidemia)
- Aspergillus*:** allergic bronchopulmonary aspergillosis (ABPA), invasive aspergillosis, aspergilloma
- Cryptococcus*:** chronic meningitis, pneumonia (especially in AIDS)
- Mucor*:** rhinocerebral mucormycosis in diabetics with ketoacidosis
- Pneumocystis jirovecii*:** interstitial pneumonia (PCP) in AIDS




Cryptosporidium parvum

Laboratory Diagnosis

- Microscopy:** KOH mount, silver stains, India ink (*Cryptococcus*)
- Culture:** Sabouraud dextrose agar
- Antigen testing:** cryptococcal antigen, galactomannan (*Aspergillus*), β -D-glucan
- PCR & imaging** (CT scan shows halo sign in aspergillosis)

Treatment

- Candida*:** fluconazole, echinocandins (e.g., caspofungin)
- Aspergillus*:** voriconazole (first-line), isavuconazole
- Cryptococcus*:** amphotericin B + flucytosine, then fluconazole
- Mucor*:** surgical debridement + amphotericin B
- Pneumocystis*:** TMP-SMX (cotrimoxazole), prophylaxis in HIV



Aspergillus species

Prevention & Control

- Prophylactic antifungals in high-risk patients
- Antiretroviral therapy in HIV
- Good catheter hygiene, control of diabetes
- Minimize immunosuppression when possible

Fungi

Opportunistic Mycoses



Name



Virulence Factors



Morphology



Clinical Manifestations



Habitat & Reservoir



Laboratory Diagnosis



Pathogenic Form



Treatment



Infective Agents



Prevention & Control



Retroviridae

Genome

Single-stranded, positive-sense RNA (2 copies per virion)

Envelope

Yes

Genera & Viruses

1. HIV-1 (Human Immunodeficiency Virus type 1)
2. HIV-2 (less common, slower progression of AIDS)
3. HTLV-1 (Human T-cell Leukemia Virus type 1)
4. HTLV-2

Transmission

Route	Details
Sexual Contact	Unprotected vaginal, anal, or oral sex with an infected partner
Parenteral (Blood)	Sharing needles or syringes, blood transfusions (rare today), organ transplants
Vertical Transmission	From mother to baby during pregnancy, childbirth, or breastfeeding
Organizational Exposure	Health-care workers or caregivers in contact with infected blood or tissues

Pathogenesis

1. **Entry:** gp120 binds CD4 & co-receptors (CCR5 early, CXCR4 late)
2. **Fusion & Uncoating:** gp41 mediates fusion
3. **Reverse Transcription:** Viral RNA $\rightarrow$ DNA via reverse transcriptase
4. **Integration:** Provirus integrates into host DNA (via integrase)
5. **Latency or Activation:** Depending on host cell activation state
6. **Assembly & Budding:** New virions formed and released

Disease

- HIV-1 & HIV-2 $\rightarrow$ AIDS (Acquired Immunodeficiency Syndrome)
 - Destroys CD4+ T cells
 - Opportunistic infections and cancers
- HTLV-1 $\rightarrow$ Adult T-cell leukemia/lymphoma (ATLL)
- HTLV-2 $\rightarrow$ Myelopathy/neurologic syndromes (rare)

Diagnosis


- HIV: ELISA (screening), Western blot/PCR (confirmation)
- CD4 count & viral load monitoring for disease progression

Treatment & Prevention

- ART (Antiretroviral Therapy): Combination of
 - NRTIs (e.g. zidovudine)
 - NNRTIs
 - Protease inhibitors
 - Integrase inhibitors
 - Entry inhibitors

Buzzwords

- "Diploid genome" $\rightarrow$ Only RNA virus with 2 copies of RNA
- "Reverse transcriptase" $\rightarrow$ Converts RNA $\rightarrow$ DNA
- "Integration into host DNA" $\rightarrow$ Leads to lifelong infection
- "gp120/gp41" $\rightarrow$ Surface proteins of HIV
- "CD4 and CCR5/CXCR4" $\rightarrow$ Entry receptors for HIV



Staphylococci

Name

Genus: *Staphylococcus*
Clinically important species: *S. aureus*, *S. epidermidis*, *S. saprophyticus*

Morphology & Staining

Gram-positive cocci arranged in grape-like clusters. Non-motile, non-spore-forming. Stains purple on Gram stain.

Culture & Growth

Facultative anaerobes. Grow on Blood agar, Nutrient agar, Mannitol Salt Agar (MSA).

- S. aureus*: Ferments mannitol (yellow colonies), beta-hemolytic
- S. epidermidis* & *S. saprophyticus*: Do not ferment mannitol

Biochemical Characteristics

All are catalase positive.

- S. aureus*: Coagulase positive
- S. epidermidis* & *S. saprophyticus*: Coagulase negative
- S. saprophyticus*: Novobiocin resistant
- S. epidermidis*: Novobiocin sensitive

Virulence Factors


- S. aureus*: Protein A, coagulase, hemolysins, leukocidins, exfoliative toxins, TSST-1
- S. epidermidis*: Forms biofilms on prosthetic materials

Pathogenesis

Entry through skin breaches, wounds, or inserting medical devices. Bacteria produce toxins and evade the immune system, leading to localized or systemic infections.



The test for catalase is performed by adding 3% hydrogen peroxide to a colony on an agar plate. Catalase-positive cultures produce O_2 and bubble immediately.



Clinical Manifestations

- S. aureus*:
 - Skin and soft tissue infections**: Impetigo, cellulitis, furuncles (boils), carbuncles
 - Abscesses**: Deep tissue and organ abscesses
 - Pneumonia**: Especially post-viral or hospital-acquired
 - Osteomyelitis & Septic arthritis**
 - Endocarditis**: Particularly in IV drug users
 - Scalded Skin Syndrome**: Due to exfoliative toxins
 - Toxic Shock Syndrome**: TSST-1 mediated
 - Food poisoning**: Due to enterotoxin (preformed toxin)
- S. epidermidis*:
 - Infections of prosthetic devices, catheters, shunts, and artificial heart valves
 - Often causes hospital-acquired bacteremia
- S. saprophyticus*:
 - Urinary tract infections (UTIs) in sexually active young females



Laboratory Diagnosis

Gram stain of sample, culture on Blood agar or MSA, catalase and coagulase tests, novobiocin sensitivity testing, and antibiotic susceptibility (e.g. for MRSA)

Treatment

- S. aureus*: Nafcillin or oxacillin for MSSA; Vancomycin or Linezolid for MRSA
- S. epidermidis*: Vancomycin (most strains are methicillin-resistant)
- S. saprophyticus*: Nitrofurantoin or trimethoprim-sulfamethoxazole (TMP-SMX)

Prevention & Control

Strict hand hygiene, sterile procedures in hospital settings, screening and decolonization for MRSA carriers, proper care of medical devices.

BACTERIA

Staphylococci

Gram-Positive (Cocci)

 Name

 Pathogenesis

 Morphology & Staining

 Clinical Manifestations

 Culture & Growth

 Laboratory Diagnosis

 Biochemical Characteristics

 Treatment

 Virulence Factors

 Prevention & Control

Free-living Bacteria

Gram-positive

Gram-negative

Cocci

Rods

Staphylococcus

Staphylococcus aureus Ⓢ

Staphylococcus epidermidis Ⓢ

Staphylococcus saprophyticus Ⓢ

Enterococcus

Peptostreptococcus

Streptococcus

BACTERIA

Mind Map

